Commentary

Video

Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC

Author(s):

David B. Zhen, MD,Samuel Cytryn, MD

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
View More
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Related Content
The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.
June 22nd 2025

Five Under 5: Top Oncology Videos for the Week of 6/15

Kate Gasparini, PharmD, BCOP, BCPPS, pediatric oncology clinical pharmacy specialist, Memorial Sloan Kettering Cancer Center
June 17th 2025

Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS

Vulvar Cancer | Image Credit: © freshidea - stock.adobe.com
Published: June 20th 2025 | Updated: June 20th 2025

Pembrolizumab Plus Chemoradiation Hits ORR End Point in Unresectable Vulvar Cancer

Michael J. Mauro, MD, attending physician, Memorial Sloan Kettering Cancer Center
May 19th 2025

Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.
June 14th 2025

The OncFive: Top Oncology Updates for the Week of 6/8

Gastroenteropancreatic NETs | Image by Ashling Wahner & MJH Life Sciences Using AI
June 12th 2025

FDA Grants Fast Track Designation to CHM CDH17 for Gastroenteropancreatic NETs